Inclusion Criteria:

- Female patients with histological or cytological proven diagnosis of breast cancer

- Stage IV disease

- Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale

- Patients had to have previously received anthracycline based regimens as a adjuvant
therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic
disease

- Adequate organ function

Exclusion Criteria:

- Prior chemotherapy for metastatic disease

- Previous radiation therapy is allowed but must not have included whole pelvis
radiation

- Known or suspected brain metastasis. Serious concomitant disorders that would
compromise the safety of the patient or compromise the patient's ability to complete
the study, at the discretion of the investigator

- Concurrent administration of any other tumor therapy, including cytotoxic
chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))

- Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History
of significant neurological or mental disorder, including seizures or dementia